Effect of electroencephalography based infraslow neurofeedback on pain and function in individuals with chronic low back pain: A pilot double-blind randomised controlled study.

Dr Divya Adhia0 个研究点目标入组 60 人开始时间: 2020年3月27日最近更新: 2024年8月26日

适应症

试验速览

暂无简介。

•Participants with a diagnosis of CLBP will be eligible to participate. To be included in the study, participants must meet all of the following inclusion criteria:
•Capable of understanding and signing an informed consent form
•Age between 18 to 75 years on the day of the consent
•Pain in the lower back area (region between the 12th rib and the gluteal fold) that occurs every day for more than or equal to 3 months
•A score of more than or equal to 4 on the 11-point numeric pain rating scale (NPRS, 0 is No pain to 10 is Worst pain) in the past 4 weeks
•A disability score of more than or equal to 5 on Roland–Morris Disability Questionnaire

•Inflammatory arthritis
•Undergoing any therapy from a health professional (e.g. physiotherapists or chiropractor)
•Recent soft tissue injuries of the back in the last 3 months
•History of surgery to the back region
•Radicular pain and radiculopathy
•History of neurological diseases
•Unstable medical or psychiatric conditions
•History of epilepsy or seizures
•Presence of any peripheral neuropathy or vascular pathology
•Sleep Apnoe
•Hearing problems (hearing loss or tinnitus)
•Alcohol or substance abuse
•Dyslipidaemia
•Cognitive impairments (dementia, post-traumatic stress disorders, Alzheimer’s disease): A total score of 24 or below on Mini-Mental State Examination
•History of uncontrolled/untreated hypertension
•Presence of any pacemaker or defibrillator
•Presence of any electronic implants or metal implant in the body (particularly head and neck)
•Recent or current pregnancy
•Participants who, in the opinion of the investigators, do not understand the information and procedures of the study, or would not be compliant with them.
•Participants with current intake of any centrally acting medications (e.g. antidepressants, anticonvulsants, neuropathic pain drugs) or intention of taking new medications in the next 3 months.

发起方

Dr Divya Adhia